Clinical trial
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
NCT00098254 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00098254 |
|---|---|
| Title | BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | BAY 43-9006 (Sorafenib) |
| Enrollment | 37 |
| Start date | Dec 1, 2004 |
| Primary completion | Nov 1, 2009 |
| Completion | Jan 1, 2011 |
| First posted | Dec 6, 2004 |
| Last update posted | May 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: